Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (1-10 of 252) with videos related to

Pageof 26
Sort By:
Cancer Treatment and Research|February 21, 2008
CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosisPeter Borchmann
Leukemia & Lymphoma|November 17, 2010
Caring beyond cure: quality of life after high-dose chemotherapy for patients with relapsed Hodgkin lymphomaPeter Borchmann
Hematology/Oncology Clinics of North America|November 30, 2013
Early intensification treatment approach in advanced-stage Hodgkin lymphomaPeter Borchmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin LymphomaPeter Borchmann, Andreas Engert
Idrugs : the Investigational Drugs Journal|June 6, 2003
Pixantrone (Novuspharma)Peter Borchmann, Marcel Reiser
Hematology. American Society of Hematology. Education Program|January 18, 2011
The past: what we have learned in the last decadePeter Borchmann, Andreas Engert
Expert Opinion on Investigational Drugs|July 30, 2005
The role of pixantrone in the treatment of non-Hodgkin's lymphomaPeter Borchmann, Roland Schnell
Hematology/Oncology Clinics of North America|November 30, 2013
Hematology/Oncology Clinics of North America. Hodgkin lymphoma. PrefaceVolker Diehl, Peter Borchmann
Current Opinion in Molecular Therapeutics|April 14, 2006
SGN-30 (Seattle genetics)Roland Schnell, Peter Borchmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Reply to H.J.A. Adams et al, E.A. Hawkes et al, and C.F. Hess et alPeter Borchmann, Andreas Engert
Pageof 26

Showing results (1-10 of 252) with videos related to

Sort By:
Pageof 26
Cancer Treatment and Research|February 21, 2008
CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosisPeter Borchmann
Leukemia & Lymphoma|November 17, 2010
Caring beyond cure: quality of life after high-dose chemotherapy for patients with relapsed Hodgkin lymphomaPeter Borchmann
Hematology/Oncology Clinics of North America|November 30, 2013
Early intensification treatment approach in advanced-stage Hodgkin lymphomaPeter Borchmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin LymphomaPeter Borchmann, Andreas Engert
Idrugs : the Investigational Drugs Journal|June 6, 2003
Pixantrone (Novuspharma)Peter Borchmann, Marcel Reiser
Hematology. American Society of Hematology. Education Program|January 18, 2011
The past: what we have learned in the last decadePeter Borchmann, Andreas Engert
Expert Opinion on Investigational Drugs|July 30, 2005
The role of pixantrone in the treatment of non-Hodgkin's lymphomaPeter Borchmann, Roland Schnell
Hematology/Oncology Clinics of North America|November 30, 2013
Hematology/Oncology Clinics of North America. Hodgkin lymphoma. PrefaceVolker Diehl, Peter Borchmann
Current Opinion in Molecular Therapeutics|April 14, 2006
SGN-30 (Seattle genetics)Roland Schnell, Peter Borchmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Reply to H.J.A. Adams et al, E.A. Hawkes et al, and C.F. Hess et alPeter Borchmann, Andreas Engert
Pageof 26